Back to top
more

Stryker (SYK)

(Delayed Data from NYSE)

$374.94 USD

374.94
1,478,016

-5.92 (-1.55%)

Updated Aug 6, 2025 04:00 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value C Growth A Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 37% (156 out of 246)

Industry: Medical - Products

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Shockwave Medical (SWAV) Up on Potential Acquisition Rumors

by Zacks Equity Research

Shockwave Medical's (SWAV) shares gain as rumors about its potential acquisition by an industry giant get media attention.

Zacks Equity Research

Boston Scientific (BSX) and Scivita Medical Expand Partnership

by Zacks Equity Research

Boston Scientific (BSX) and Scivita Medical announce an expanded strategic cooperation arrangement.

Zacks Equity Research

Here's Why Investors Should Retain Thermo Fisher (TMO) Stock

by Zacks Equity Research

Strength in end markets and strategic collaborations bode well for Thermo Fisher (TMO).

Zacks Equity Research

Abbott's (ABT) Assert-IQ Cardiac Monitor Receives CE Mark

by Zacks Equity Research

Abbott's (ABT) Assert-IQ ICM enables regular monitoring for abnormal heart rhythms, as well as technologies to improve data management and workflow.

Zacks Equity Research

Here's Why You Should Buy Zimmer Biomet (ZBH) Stock Now

by Zacks Equity Research

Investors are optimistic about Zimmer Biomet (ZBH), led by expansion in the knee business and recovery across the business.

Zacks Equity Research

Stryker's (SYK) Latest Launch to Streamline Procedural Workflows

by Zacks Equity Research

Stryker's (SYK) latest addition to its Gamma legacy is expected to streamline workflows and enhance usability.

Zacks Equity Research

Myriad Genetics (MYGN) Wins Foundational Patent for MRD Assay

by Zacks Equity Research

Myriad Genetics' (MYGN) new patent grant is likely to bolster the ability to deliver a tumor-informed, high-definition MRD assay to the market.

Zacks Equity Research

Masimo (MASI) Plans Consumer Business Spin-Off to Drive Growth

by Zacks Equity Research

Masimo (MASI) is evaluating a proposed separation of its consumer audio and consumer health product business in a bid to improve the profitability of the healthcare business.

Zacks Equity Research

Reasons to Retain Intuitive Surgical (ISRG) in Your Portfolio

by Zacks Equity Research

Intuitive Surgical (ISRG) continues to raise optimism among investors, owing to its strength in robotics.

Zacks Equity Research

QIAGEN (QGEN) Unveils QIAstat-Dx Analyzer With Remote Access

by Zacks Equity Research

With QIAGEN's (QGEN) QIAstat-Dx Analyzer 2.0's integration of remote access, central and regional laboratories may work together efficiently, particularly when it comes to decentralized testing.

Zacks Equity Research

Charles River (CRL) Extends Gene Therapy Deal With NUS Medicine

by Zacks Equity Research

Charles River (CRL) announces the extension of the gene therapy manufacturing alliance with NUS Medicine.

Zacks Equity Research

Here's Why You Should Buy Align Technology (ALGN) Stock Now

by Zacks Equity Research

Investors remain optimistic about Align Technology (ALGN), backed by Invisalign's strong potential and impressive collaborations.

Zacks Equity Research

Tandem Diabetes (TNDM) Gains From Innovation Amid Competition

by Zacks Equity Research

Tandem Diabetes (TNDM), in 2024, intends to advance its AID algorithm and expand its indications to include people living with Type 2 diabetes.

Zacks Equity Research

Stryker (SYK) Acquires SERF SAS to Aid Its Orthopedic Segment

by Zacks Equity Research

Stryker (SYK) completes its acquisition of SERF SAS, a France-based joint replacement company. With this acquisition, Stryker aims to boost its orthopedic division in the European region.

Zacks Equity Research

Bruker Corporation (BRKR) Hits 52-Week High: What's Driving It?

by Zacks Equity Research

Bruker Corporation (BRKR) outperforms the industry due to its strengthening portfolio and robust quarterly results.

Zacks Equity Research

Phibro Stock (PAHC) Rises 7% YTD: Will the Run Continue?

by Zacks Equity Research

Investors are optimistic about Phibro (PAHC), led by the introduction of new products and upbeat guidance.

Zacks Equity Research

The Zacks Analyst Blog Highlights Disney, Morgan Stanley, Stryker, Shopify and Delta Air Lines

by Zacks Equity Research

Disney, Morgan Stanley, Stryker, Shopify and Delta Air Lines are included in this Analyst Blog.

Mark Vickery headshot

Top Stock Reports for Disney, Morgan Stanley & Stryker

by Mark Vickery

Today's Research Daily features new research reports on 16 major stocks, including The Walt Disney Company (DIS), Morgan Stanley (MS) and Stryker Corporation (SYK).

Zacks Equity Research

Reasons to Add Stryker (SYK) Stock in Your Portfolio Now

by Zacks Equity Research

Stryker (SYK) continues to benefit from strength in the robotic arm-assisted surgery platform, Mako, and its broad product portfolio.

Zacks Equity Research

Here's Why You Should Retain National Vision (EYE) Stock Now

by Zacks Equity Research

The strong execution of strategic initiatives and robust financial stability bode well for National Vision (EYE).

Zacks Equity Research

Walgreens' (WBA) AllianceRx Pharmacy Will Distribute VIVJOA

by Zacks Equity Research

Walgreens' (WBA) specialty pharmacy patients now have exclusive access to 240+ limited distribution drugs.

Zacks Equity Research

Here's Why Investors Should Buy Phibro (PAHC) Stock Now

by Zacks Equity Research

Phibro's (PAHC) diversified offerings and prospering vaccine business buoy optimism for investors.

Zacks Equity Research

Align Technology (ALGN) Gains From Innovation, Macro Issues Ail

by Zacks Equity Research

In terms of innovation, Align Technology successfully launched its first subscription-based clear aligner program Doctor Subscription Program (DSP) worldwide.

Zacks Equity Research

Here's Why Investors Should Retain Abbott (ABT) Stock Now

by Zacks Equity Research

Investors are optimistic about Abbott (ABT), led by solid prospects in the Diagnostic business and robust adoption of FreeStyle Libre.

Zacks Equity Research

Edwards Lifesciences (EW) Up 21.8% YTD: What's Driving It?

by Zacks Equity Research

Investors are optimistic about Edwards Lifescience's (EW) substantial growth across each of its four product groups.